Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-06-0677
European Journal of Endocrinology, Vol 156, Issue 4, 425-430
Copyright © 2007 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brignardello, E.
Right arrow Articles by Boccuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brignardello, E.
Right arrow Articles by Boccuzzi, G.

CLINICAL STUDY

Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years

Enrico Brignardello1, Marco Gallo1, Ileana Baldi2, Nicola Palestini3, Alessandro Piovesan1, Emidio Grossi1, Giovannino Ciccone2 and Giuseppe Boccuzzi1,4

1 Oncological Endocrinology Unit and 2 Cancer Epidemiology Unit, San Giovanni Battista Hospital, Turin, Italy, 3 Departments of Surgery and 4 Clinical Pathophysiology, University of Turin, Turin, Italy

(Correspondence should be addressed to G Boccuzzi who is now at Department of Clinical Pathophysiology, Via Genova, 3, 10126 Turin, Italy; Email: giuseppe.boccuzzi{at}unito.it)

Objective: Treatment options for anaplastic thyroid carcinoma (ATC), which is one of the most lethal human malignant tumors, include surgery, chemotherapy and radiotherapy usually combined in a multimodal approach, to improve survival and avoid death from local invasion. However, there is no standard protocol for ATC treatment and the optimal sequence within multimodal therapy is debated. We retrospectively report the clinical outcome of 30 ATC patients referred consecutively to the Oncological Endocrinology Unit of San Giovanni Battista Hospital (Turin, Italy) between 2000 and 2005.

Design: Patients were treated by one of the following approaches: i) surgery followed by adjuvant-combined chemoradiotherapy; ii) neo-adjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy; or iii) chemotherapy alone. The surgical procedures were classified as ‘maximal debulking’ or ‘palliative resection’. Maximal debulking entailed total or near-total thyroidectomy and complete resection of all gross tumor or minimal residual disease adherent to vital structures, independently of the presence or absence of distant metastases. In palliative resections, macroscopic residual disease was left in the neck. Survival of patients stratified by treatment was assessed.

Results: Analysis of multivariate hazard ratios showed that maximal debulking followed by adjuvant chemoradiotherapy was the only treatment that modified survival of ATC patients (hazard ratio= 0.23, 95% CI: 0.07–0.79), even if factors determining poor prognosis or increased surgical risk were present.

Conclusions: Despite the overall grim outcome of ATC, these results justify an attempt at maximal debulking surgery, followed by adjuvant chemoradiotherapy, possibly in all ATC patients.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
M. G Catalano, R. Poli, M. Pugliese, N. Fortunati, and G. Boccuzzi
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines
Endocr. Relat. Cancer, September 1, 2007; 14(3): 839 - 845.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 European Society of Endocrinology.